Citation Impact
Citing Papers
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
2017
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation
2017
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
2014
Nicotine Chemistry, Metabolism, Kinetics and Biomarkers
2009 Standout
Psoriasis
2014
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease
2018
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
2015
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 Standout
NF-κB signaling in inflammation
2017 Standout
Clinical improvement in psoriasis with specific targeting of interleukin-23
2015 Nature
IL-12 protects from psoriasiform skin inflammation
2016
Research gaps in psoriasis: Opportunities for future studies
2013
Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
2014
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
2017
Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR )
2019
Safety evaluation of topical applications of ethanol on the skin and inside the oral cavity
2008 Standout
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
2015
Psoriasis
2021 Standout
Psoriasis: Which therapy for which patient
2018
State of the art in hair analysis for detection of drug and alcohol abuse
2006 Standout
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study
2015
Design and Implementation Content Validity Study: Development of an instrument for measuring Patient-Centered Communication
2015 Standout
Psoriasis
2015 Standout
Relevance of the developmental toxicity of ethanol in the occupational setting: a review
2003
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Crohn's disease
2016 Standout
Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review
2014
IL-12-and IL-23 in health and disease
2014
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
2015
Glycosylation changes in inflammatory diseases
2019
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
2015
Hidradenitis suppurativa
2020 Standout
Flavonoids: an overview
2016 Standout
Inflammatory processes in cardiovascular disease: a route to targeted therapies
2016
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Psoriasis
2016
Macrophage Cytokines: Involvement in Immunity and Infectious Diseases
2014 Standout
Anti-IL-12/IL-23p40 antibody ameliorates dermatitis and skin barrier dysfunction in mice with imiquimod-induced psoriasis-like dermatitis
2018
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
2018 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Glycoproteomics
2022 StandoutNobel
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis
2016
Antidrug antibodies in psoriasis: a systematic review
2013
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
2014
Erratum: Inflammatory processes in cardiovascular disease: a route to targeted therapies
2017
Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a
2016
Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints
2018
Psoriasis Pathogenesis and Treatment
2019 Standout
Relationship of Human Toenail Nicotine, Cotinine, and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol to Levels of These Biomarkers in Plasma and Urine
2007
‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network
2014
Conversion of Daidzein and Genistein by an Anaerobic Bacterium Newly Isolated from the Mouse Intestine
2008
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis
2015
In Vitro Contamination of Hair by Marijuana Smoke
2004
Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis
2011
Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease
2019
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
2020 Standout
Works of Daphne Chan being referenced
Recent developments in meconium and hair testing methods for the confirmation of gestational exposures to alcohol and tobacco smoke
2004
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn’s Disease
2019
Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study
2012
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
2018
Estimation of Fetal Exposure to Drugs of Abuse, Environmental Tobacco Smoke, and Ethanol
2002
Serum equol, bone mineral density and biomechanical bone strength differ among four mouse strains
2005
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
2013
Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up
2014
Endoscopic Healing in Induction and Maintenance with Ustekinumab in the Phase 3 UNITI Crohnʼs Disease Program: 2016 ACG Presidential Poster Award
2016
Efficacy of Ustekinumab for Induction and Maintenance of Histological Healing in patient's with Crohn’s Disease
2017
A Canadian Self-Administered Online Survey to Evaluate the Impact of Moderate-to-Severe Psoriasis among Patients
2009
SAT0267 Safety of Ustekinumab from the Placebo-Controlled Periods of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs
2013